Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients

INTRODUCTION: Advances in genomic techniques have been valuable in guiding decisions regarding the treatment of early breast cancer (EBC) patients. These multigene assays include Oncotype DX, Prosigna, and Endopredict. There has generally been a tendency to overtreat or undertreat patients, and havi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Oncol
Autors principals: Assi, Hazem I., Alameh, Ibrahim A., Khoury, Jessica, Abdul Halim, Nour, El Karak, Fadi, Farhat, Fadi, Berro, Juliett, Sbaity, Eman, Charafeddine, Maya, Tfayli, Arafat, Salem, Ziad, El Saghir, Nagi
Format: Artigo
Idioma:Inglês
Publicat: Hindawi 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7719508/
https://ncbi.nlm.nih.gov/pubmed/33312202
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/9238084
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars